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BACKGROUND. To the authors’ knowledge, no effective medical therapy currently is
available for advanced chordoma. Imatinib mesylate is a tyrosine kinase inhibitor
targeting platelet-derived growth factor receptor- (PDGFRB), BCR-ABL, and KIT.
METHODS. Six patients with advanced chordoma were treated with imatinib me-
sylate at a dose of 800 mg daily. In all patients, the tumor was found to be positive
for PDGFRB, and in four patients PDGFRB was shown to be phosphorylated/
expressed.
RESULTS. After a treatment period of  1 year, overt tumor liquefaction was
evident on computed tomography (CT) scan in the ﬁrst patient. In previous
months, a decrease in contrast enhancement on magnetic resonance imaging
(MRI) and a decrease in glucose uptake on positron emission tomography (PET)
were detected. Similar signs on MRI and PET were observed in subsequent
patients, who had a shorter treatment period. One of these patients initially was
removed from therapy and then was readmitted to therapy because of difﬁcul-
ties with regard to tumor response assessment; 1 month after the reinitiation of
therapy, an overt decrease in tumor density was visible on CT scan in this
patient. In four of ﬁve symptomatic patients, a subjective improvement was
observed early in the course of treatment. The ﬁrst patient died after 17 months,
with a sizeable, mostly liqueﬁed mass. Another patient died early, apparently of
unrelated causes. The remaining patients were on therapy at the time of last
follow-up.
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CONCLUSIONS. Imatinib mesylate has been found to have antitumor activity in
patients with chordoma. This activity might be mediated by inactivation of PDG-
FRB. Tumor response manifests through patterns that are similar to those observed
in patients with gastrointestinal stromal tumors who respond to molecular-tar-
geted therapy, but evolves more slowly. The beneﬁt to the patient entailed by this
pattern of tumor response in chordoma needs to be elucidated, but may be limited
in the presence of signiﬁcant local disease. Cancer 2004;101:2086–97.
© 2004 American Cancer Society.
KEYWORDS: chordoma, imatinib mesylate, tyrosine kinase inhibitor, platelet-derived
growth factor receptor- (PDGFRB), response.
Chordomas are very rare tumors, with an incidenceof approximately, or slightly lower than, 0.1/
100,000/year.1 They originate from remnants of the
notochord.2 Chordomas arise from the sacrum in ap-
proximately 50–60% of cases, from the skull base re-
gion in approximately 25–35% of cases, and from the
cervical and thoracolumbar vertebrae in approxi-
mately 15% of cases (10% from the cervical vertebrae
and 5% from the thoracolumbar vertebrae). They are
low-grade tumors and display a typical clinical pre-
sentation, with lobules and vacuolated (physalipho-
rous), moderately atypical, neoplastic cells across a
myxoid stroma separated by ﬁbrous bands. They gen-
erally grow slowly at the primary tumor site. Pain is
the cardinal symptom, whereas neurologic deﬁcits are
reported to vary according to the size, shape, and
location of the lesion(s). Distant metastases can occur,
and these also demonstrate a slow pattern of growth.
Conversely, “dedifferentiated” chordoma is observed
in  5% of cases, with features of a high-grade spindle
cell sarcoma. Epidemiologically, the median survival
has been estimated to be approximately 6 years, with
a survival rate of 70% at 5 years, falling to 40% at 10
years.1 However, after the development of metastases,
the median survival was reported to be  12 months
in a series of chordoma patients seen at our institu-
tion.3
The standard treatment for chordoma is surgery.
However, a proportion of chordoma patients (approx-
imately 50–70%) are not cured of their disease and
ultimately die. If death is a late event, the patient’s
quality of life generally is compromised across the
relentless natural history of the disease because of the
anatomic location of the tumor.3–6 Radiation therapy
is employed either as an adjuvant to subtotal resec-
tion, as a deﬁnite treatment modality when surgery is
clearly unfeasible, or as palliative therapy. Anatomic
constraints imply obvious technical problems,7 and
new techniques have been employed in an effort to
provide adequate radiation doses while limiting the
risk of injury to functionally vital structures.8–11 Most
likely because of their low malignancy grade, chordo-
mas are not reported to be sensitive to chemotherapy.
To our knowledge, no drug or regimen has been re-
ported to date to be active in chordomas. Anecdotal
reports of tumor responses are available, but the re-
sponse rate to whatever chemotherapy regimen was
used can be assumed to be deﬁnitely low.12,13.
Imatinib mesylate (Gleevec
™
[Glivec®], Novartis
Pharma AG, Basel, Switzerland) is an inhibitor of some
tyrosine kinases, mainly BCR-ABL, KIT, and platelet-
derived growth factor receptor- (PDGFRA) and plate-
let-derived growth factor receptor- (PDGFRB). Its in-
hibition of BCR-ABL and KIT underlies its efﬁcacy in
the treatment of chronic myeloid leukemia14 and gas-
trointestinal stromal tumors (GIST), respectively.15–17
This efﬁcacy has been conﬁrmed through large pro-
spective clinical studies.18–20 Other tumors also have
been assessed for imatinib mesylate activity. To our
knowledge to date, antitumor activity has been re-
ported in dermatoﬁbrosarcoma protuberans,21 in
which it is mediated through the inhibition of PDG-
FRB, and aggressive ﬁbromatosis.22
In August 2002, at the Istituto Nazionale per lo
Studio e la Cura dei Tumori in Milan, Italy, a tumor
sample from a patient with an advanced chordoma
was tested for molecular targets of potential clinical
interest, including PDGFRB. The protein was dem-
onstrated to be expressed and activated. It was spec-
ulated that an autocrine loop activating this growth
factor receptor could be operating, and, because of
the lack of standard therapeutic options, the patient
agreed to undergo treatment with imatinib mesy-
late. Therapy was initiated in August 2002. Subjec-
tive improvement was observed, and therapy was
maintained. Within some months, both magnetic
resonance imaging (MRI) and positron emission to-
mography (PET) scans suggested some type of anti-
tumor activity. At that stage, an additional ﬁve pa-
tients were administered therapy, starting from
April 2003 to July 2003. This article reports on clin-
ical observations made with regard to these pa-
tients.
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MATERIALS AND METHODS
In six patients with a histologically conﬁrmed diagno-
sis of chordoma, the presence of PDGFB was assessed
by reverse transcriptase-polymerase chain reaction
(RT-PCR), in which RNA extracted from a tumor bi-
opsy was analyzed. All patients were found to demon-
strate positive expression of PDGFB. Phosphorylation/
expression of PDGFB was demonstrated by
immunoprecipitation and Western blot analysis be-
fore the beginning of treatment in Patient 1 and ret-
rospectively on pretreatment biopsies taken from Pa-
tients 2, 5, and 6. The remaining two patients did not
demonstrate phosphorylation/expression, most likely
because the amount of tumor material used for total
protein extraction was insufﬁcient.
Staging was performed using local MRI and/or
computed tomography (CT) scans in all patients, PET
scans in all patients but one, and chest CT scans/chest
X-rays. During treatment, MRI and/or CT scans were
repeated at intervals of 1–3 months. PET scan was
repeated at similar intervals in most patients.
All patients received imatinib mesylate on an in-
dividual basis, in light of the lack of any potentially
effective surgical and/or radiation therapy option, af-
ter written informed consent was provided. The pa-
tients were aware of the nature of their disease and of
the unproven value of the proposed therapy. The drug
was provided free of charge by Novartis Pharma AG.
All patients received imatinib mesylate at a dose of 800
mg daily. No major adverse effects were observed.
Side effects normally associated with imatinib mesy-
late were reported, but no patient had to discontinue
therapy because of toxicity for more than a few weeks.
Case Reports
Patient 1 was diagnosed with a sacral chordoma at the
age of 52 years. In 1993, he underwent a posterior
sacral amputation (S2-3). A local recurrence develop-
ing after 3 years was treated with surgical curettage
and radiation therapy (44  13 grays [Gy]). After 3
years, a multifocal recurrence to the sacral and gluteal
regions was treated with debulking surgery. At that
time, bilateral, small metastases of the lung were de-
tected. Further debulking surgery was performed after
1 year. In August 2002, progressive locoregional dis-
ease was evident, and the patient began treatment
with imatinib mesylate at a dose of 800 mg daily in 2
refracted doses. In the early months after the initiation
of therapy, the patient demonstrated some early sub-
jective improvement in terms of the greater softness of
the tumor mass palpable in the buttocks and an im-
provement in pain. At the beginning of the treatment,
there was moderate neuropathic and somatic pain,
and the patient was being treated with 60 mg of slow-
release oral morphine given 3 times daily, plus gaba-
pentin, dexamethasone, and 10 mg of short-release
oral morphine as needed. Soon after the initiation of
treatment with imatinib mesylate, an increase in the
sensation of stabbing and lancinating pain to the glu-
teal region and the lower limb was reported, necessi-
tating an increase in the dose of gabapentin given.
However, after 2 months of therapy, 1) the daily dose
of analgesics was not increased, nor were rescue doses
used; 2) a decrease in pain was reported, being mild
when the patient was sitting and absent when the
patient was supine; and 3) the dose of morphine could
be decreased from 60 mg 3 times daily to 30 mg twice
a day. On MRI, the lesion was judged to be slightly
increasing in size in the ﬁrst months, with some re-
shaping of the tumor noted in the buttocks, possibly
related to its decreased ﬁrmness. Between 2 months
and 8 months from treatment start, MRI scan dem-
onstrated stable disease (Fig. 1A). However, with in-
travenous paramagnetic contrast medium (gadolini-
um-diethylenetriamine pentaacetic acid [Gd-DTPA]),
the contrast enhancement (Fig. 1B) was found to be
substantially lower. This major decrease in contrast
enhancement was found to be correlated with a de-
crease in glucose uptake on the PET scan between 2
months and 6 months (Fig. 2). Between 8 months
and 14 months, the tumor aspect on T1-weighted,
contrast-enhanced images was found to be the same,
with high-signal intensity noted on T2-weighted im-
ages. At this time, CT scan demonstrated distinct signs
of tumor liquefaction (Fig. 3A) in a substantial portion
of the tumor volume (Fig. 3B). Clinically, this paved
the way for a spontaneous spillage from the buttocks
of a dense ﬂuid with overt tumor debris. Figure 4
shows the histologic aspect of the spillage, which was
consistent with marked tumor regressive changes
along with apoptotic ﬁgures. Biochemical analyses were
performed on the tumor material, and a nonphospho-
rylated, inactive PDGFRB was detected (Fig. 5). In the
interim, lung metastases remained unchanged, as did
glucose uptake on the PET scan. Pain was controlled
with a daily dose of 60 mg of morphine. Conversely,
tumor liquefaction required special local care and was
found to impair the daily life of the patient to a signiﬁ-
cant extent. The patient’s general condition worsened
progressively, apparently in connection with the persis-
tent, although mostly liqueﬁed, tumor mass, with epi-
sodes of septic fever reported. Death occurred 17
months from the initiation of treatment.
Patient 2 was diagnosed with a sacral chordoma at
the age of 25 years. He underwent curettage of the
sacrococcigeal lesion. Because of evident disease, the
patient underwent a limited excision in January 2001,
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followed by a sacral amputation (S3) 1 month later.
Radiation therapy followed (at a dose of 64 Gy). In
October 2002, a recurrence to the gluteal region oc-
curred, which was treated with a wide excision. In
April 2003, disease recurrence was evident in both
gluteal regions. Imatinib mesylate at a dose of 800 mg
daily was initiated in April 2003. One month after the
initiation of therapy, an increase in the tumor volume
was apparent. Therapy was maintained for 4 months
and then withdrawn when a further increase in tumor
volume was evident and the patient reported an in-
crease in pain. Indeed, a PET scan detected some
decrease in the glucose uptake at 1 month and 3
months. Therapy was switched to a high-dose pro-
longed infusion of ifosfamide (14 g/m2 over 14 days
through an external infusion pump), but further dis-
ease progression was detected. At this time, a clearcut
contrast enhancement was noted (Fig. 6) and it was
appreciated retrospectively that it had decreased
while the patient was receiving imatinib mesylate
therapy at 4 months, paralleling a high signal inten-
sity on T2-weighted images (i.e., the same pattern
recorded in Patient 1 after 8 months). It then was
decided to readminister imatinib mesylate. At this
stage, lung metastases became visible. One month
after therapy was readministered, the signiﬁcant lo-
coregional lesion increased in size, whereas tumor
density as observed on CT scan decreased by roughly
50% (Fig. 7). Subjectively, the mass appeared to have
increased overtly in size, but was less ﬁrm. Wide skin
ulcers became present, and necrotic debris was evi-
dent throughout these ulcers. At the time of last fol-
low-up, these ulcers required continuous local care,
although some symptoms had improved (stipsis and,
in part, pain) and the patient was able to remain in the
sitting position, whereas he was completely bedridden
FIGURE 1. Axial, T1-weighted magnetic resonance imaging scan in Patient 1. At 8 months, there was a minor decrease noted with regard to tumor size, but
the main feature observed was (B) decreased contrast enhancement (arrow).
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after the readministration of imatinib mesylate. Ther-
apy was continuing at the time of last follow-up.
Patient 3 was diagnosed with a chordoma of the
clivus in 1998 at the age of 58 years. He underwent
embolization and partial excision of the tumor, which
had a sphenoideal, ethmoidal, and nasopharyngeal
extent. Because of disease progression, the patient
underwent several surgical debulking excisions in Jan-
uary 2000, September 2000, January 2002, May 2002,
and October 2002. In April 2001, proton/photon beam
radiation therapy was administered to the residual
tumor. Treatment with imatinib mesylate was initi-
ated at a dose of 800 mg daily from May 2003 onward.
The patient died 3 months from the initiation of ther-
apy, apparently of unrelated causes. MRI scan at 2
months illustrated a decrease in contrast enhance-
ment on T1-weighted images, although with some
slight increase in the tumor volume and some signs of
FIGURE 2. A positron emission tomography (PET) scan in Patient 1. At 6 months, there was some decrease reported in the glucose uptake of the sacral/gluteal
lesion noted on the PET scan. Because of the lack of a baseline assessment, comparison was made with a pretreatment evaluation dating back several months.
FIGURE 3. Patient 1. (A) Areas of low density (expressed in Houndsﬁeld units [HU]) were visible throughout the lesion on the CT scan, with (B) low contrast
enhancement noted on T1-weighted magnetic resonance imaging from most cranial to most caudal sections.
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internal bleeding were noted at 3 months, all of
which were suggestive of an initial response. Some
initial decrease in symptoms resulting from local com-
pression (e.g., improvement in swallowing) were re-
ported by the patient.
Patient 4 was diagnosed with a sacral chordoma in
1995 when she was age 41 years. Sacral amputation
(S1-2) was performed with suboptimal surgical mar-
gins, followed by radiation therapy (at a dose of 60
Gy). Because of a pelvic disease recurrence after 5
years, a surgical excision was performed in 2000. In
June 2002, pelvic nodules were surgically excised. In
May 2003, because of the presence of evident pelvic
disease, treatment with imatinib mesylate was initi-
ated at a dose of 800 mg daily. Although there ap-
peared to be a progressive, slight increase in the tumor
volume within the ﬁrst 5 months after the initiation of
treatment, the patient presented with a consistent de-
crease in contrast enhancement (Fig. 8). PET scan
demonstrated a minor decrease in glucose uptake. At
the time of last follow-up, the patient reported that her
pain was well controlled through a dose of methadone
which had not been increased since the initiation of
treatment, whereas it needed to be continuously in-
creased earlier in the patient’s treatment.
Patient 5 was diagnosed with a sacral chordoma in
1993 at the age of 48 years. A pelvic mass was surgi-
cally excised, followed by radiation therapy (at a dose
of 40 Gy). After 6 years, proton beam radiation therapy
was given for a local recurrence (70 cobalt Gy equiv-
alent), with a partial response achieved. Liver metas-
tases were evident in 2003 and were conﬁrmed histo-
logically through a biopsy, along with local disease
progression. Imatinib mesylate at a dose of 800 mg
daily was initiated beginning in July 2003. At the time
of last follow-up, the patient was unevaluable to the
sacrum, whereas the liver lesions demonstrated some
initial decrease in size on the CT scan at 3 months
after the beginning of therapy (Fig. 9). PET scan dem-
onstrated some decrease in glucose uptake, especially
with regard to the maximum standard uptake (SUV-
max) values (from 6.7 g/mL to 5.5 g/mL). At the time
of last follow-up, the patient remained asymptomatic
and was receiving therapy.
Patient 6 underwent debulking surgery in April
2003 at the age of 73 years for a chordoma that
involved the sacrum and the left iliac wing exten-
sively, as well as the surrounding soft tissues. Treat-
ment with imatinib mesylate was initiated in July
2003 because of the presence of involvement of both
gluteal regions. The patient demonstrated some mi-
nor increase in tumor volume after the initiation of
therapy; however, the lesions demonstrated less
contrast enhancement from 2 months onward,
with high signal intensity noted on T2-weighted im-
ages. This pattern of tumor response continued to
be apparent until the last examination performed at
6 months (Fig. 10). PET scan showed a decrease in
glucose uptake after 2 months, and the glucose up-
take continued to decrease both with regard to the
median and maximum SUV through the last exam-
ination performed at 8 months. At the time of last
follow-up, the patient reported that the pain was
well controlled with the same analgesic therapy that
was administered on starting imatinib mesylate,
whereas the sacral mass appeared to be less ﬁrm,
although it had appeared to increase in size. How-
ever, at the time of last follow-up, the patient was
able to maintain a sitting position, unlike before
treatment was initiated.
FIGURE 4. Patient 1. Spontaneous spillage from the lesion of semiﬂuid material occurred, with a pathologic aspect consistent with markedly apoptotic regressive
changes.
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DISCUSSION
Of six patients with advanced chordoma and biomo-
lecular signs of involvement of PDGFRB, one demon-
strated overt liquefaction of a substantial portion of
his primary tumor after several months of therapy,
during which time indirect signs of tumor response
could be observed radiologically. A striking decrease
in tumor density also was observed in the second
patient after therapy was readministered after a tem-
porary interruption because of misinterpretation of
the same radiologic signs. These radiographic ﬁndings
have been consistently observed in the other patients
after shorter treatment intervals. Such ﬁndings mainly
were observed in terms of a decrease in contrast en-
hancement on MRI and glucose uptake on PET scans.
Some early subjective beneﬁt was observed in the
majority of patients, although, after several months,
tumor liquefaction of a signiﬁcant tumor mass did not
result in a beneﬁt for the ﬁrst patient, who ultimately
died. Likewise, the quality of life of the second patient
was greatly affected by his mostly liqueﬁed tumor
mass, although at the time of last follow-up the patient
appeared to be slowly improving. In most patients,
tumor response evolved slowly, in a way that appears
very similar to patients with GIST responding to mo-
lecular-targeted therapy. Table 1 summarizes the an-
titumor effects described above.
These chordoma patients were treated with ima-
tinib mesylate on the assumption that PDGFRB might
be implicated in tumor growth. In fact, we observed
that PDGFRB was phosphorylated/expressed in the
ﬁrst patient and PDGFB was present in all the remain-
ing patients. Retrospectively, phosphorylation/expres-
sion could be detected in the three other patients in
whom there was a sufﬁcient amount of frozen tissue
for immunoprecipitation/Western blot analysis. This
is not tantamount to a formal demonstration of the
involvement of PDGFRB in the growth process of
chordomas. However, the results of the current study
are suggestive. At the time of last follow-up, all 18
chordoma patients tested at our institution were
found to be positive for either the presence of PDGFB
or expression/phosphorylation of PDGFRB (data not
shown). Furthermore, by comparing samples ob-
tained before and after treatment in Patient 1, PDG-
FRB inactivation after therapy could be demonstrated
biochemically. Histologically, this ﬁnding was accom-
panied by the presence of distinctly apoptotic cells. In
brief, these ﬁndings strongly suggest that further in-
vestigation of the role of PDGFRB in chordomas is
necessary. However, other mechanisms of action of
imatinib mesylate cannot be excluded at the current
time.
FIGURE 5. Patient 1. Expression and phosphorylation status of platelet-derived
growth factor receptor- (PDGFRB) prior to and after treatment. (A) Expression and
phosphorylation status of PDGFRB prior to treatment (“Patient 1” compared with a
negative, “C-” and a positive control “C”). For each lane, 800 g of total protein
extracts were immunoprecipitated with PDGFRB antibody, run on gel, and blotted
with the indicated antibodies. (B) Reverse transcriptase-polymerase chain reaction
for PDGFB (ligand). A band corresponding to the ligand was detected in this patient,
as it was in all patients in the current series. MWM: standard molecular weight
marker. One microgram of RNA was retrotranscribed to cDNA and ampliﬁed with
primers speciﬁc for PDGFB (C) Expression of PDGFRB in the tumor before and after
therapy. PDGFRB was detected only before therapy. Equal amounts of total proteins
(80 g) were loaded onto a gel. The membrane was incubated with PDGFRB
antibody.
2092 CANCER November 1, 2004 / Volume 101 / Number 9
We observed an early subjective improvement in
the ﬁrst patient, and therefore treatment with imatinib
mesylate was maintained. In fact, tumor size did not
appear to change substantially over several months.
However, in this ﬁrst patient, contrast enhancement
as noted on MRI scan and glucose uptake as noted on
PET scan were found to decrease consistently in a
matter of months. A similar evolution was observed in
subsequent patients, although often in the presence of
some initial increase in tumor volume. These ﬁndings
would hardly be explicable in the absence of some
kind of antitumor activity of imatinib mesylate. In-
deed, PET scanning is the earliest and most reliable
indicator of tumor response in GIST patients treated
with the same agent (more precisely, it may be viewed
as an early “predictor” of the response of GISTs to
imatinib mesylate). Most important, those radiologic
signs were found to precede overt tumor liquefaction
in the ﬁrst two patients reported herein. We believe
that this is enough evidence to suggest that imatinib
mesylate has some type of antitumor activity in chor-
doma and that, possibly, this activity might be of ma-
jor signiﬁcance. Of course, clinical studies are needed
to quantify the response rate and evaluate the medi-
um/long-term impact of treatment in terms of survival
and quality of life.
After the experience of molecular-targeted ther-
apy in patients with GIST, it has now become well
accepted by the medical oncology community that the
tumor response manifests differently from what we
ordinarily observe with cytotoxic agents in solid neo-
plasms (as well as, paradigmatically, in lymphomas).
In GISTs, one of the most striking clinical ﬁndings has
been that the tumor response to molecular-targeted
therapy with imatinib is often manifested by: 1) early
signs of subjective improvement and a decrease in
glucose uptake on the PET scan;23 2) midterm signs of
a decrease in tumor density on the CT scan and a
change in the signal intensity on the MRI scan even
without a noticeable impact on tumor size, which
indeed also may increase;24,25 and 3) delayed signs of
a decrease in the size of the tumor and/or tumor
stabilization with altered tumor density. Histologi-
cally, signs of response are cellular depletion with
varying degrees of an apoptotic tumor cell population
and a stromal myxoid degeneration17. This most likely
reﬂects the mechanisms of action of molecular-tar-
geted therapy, with an initial “functional” effect on
FIGURE 6. Magnetic resonance imaging (MRI) in Patient 2. Despite the increase in size, lower contrast enhancement was evident after treatment with imatinib
on T1-weighted MRI. Contrast enhancement was again visible after the disease progressed after chemotherapy. HD-IFX: high-dose ifosfamide.
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tumor metabolism, followed by an effect on the char-
acteristics of the tumor tissue and eventually some
more conventional impact on tumor size. This time
evolution of the tumor response also occurred in these
patients with chordoma. However, the size of the re-
sidual masses did not appear to regress signiﬁcantly,
even after several months, so that major clinical com-
plications were encountered in the two patients who
began treatment with the largest tumor lesions. This
might be explained in at least two ways. First, the
histological hallmark of chordomas is acellular myxoid
material and a varying amount of a heterogeneous
cellular component comprised of syncythial cell cords
and/or strands arranged into lobules. Therefore, a re-
sponse with regard to tumor size may be slower
and/or less pronounced in patients with chordomas
FIGURE 7. Computed tomography (CT) scan in Patient 2. One month after therapy was reinitiated, the lesion increased in size and could not be examined in its
entirety using CT scan or magnetic resonance imaging. However, the portion that was assessable through the CT scan demonstrated an obvious decrease in the
tumor density (as expressed in Houndsﬁeld units [HU]) compared with 1 month previously.
FIGURE 8. Magnetic resonance imaging in Patient 4. Some increase in size was visible in the ﬁrst months of therapy, but it was accompanied by a higher signal
on the T2-weighted images and a decreased contrast enhancement on T1-weighted images with contrast subtraction.
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compared with those with the more cellular GIST, and
only very indirect radiologic signs may herald a late
obvious impact on the tumor. Second, the molecular
target of therapy might inﬂuence patterns of response.
In this sense, PDGFRB and related pathway(s) may act
as a competence factor, as opposed to other factors
related more directly to cell growth. However, our
impression was that similarities with GIST prevailed,
both clinically and radiologically, although on a dif-
ferent time scale. In addition, in the ﬁrst patient re-
ported herein, although after a long treatment period,
marked cellular regressive changes with a high rate of
apoptotic ﬁgures were evident histologically in the
ﬂuid that spilled out of the tumor site, a ﬁnding that is
consistent with that noted in GIST patients.
From the clinical point of view, these patterns of
response may have two implications. First, signs of
tumor response to molecularly-targeted agents have
FIGURE 9. Magnetic resonance imaging in Patient 5. Lower
contrast enhancement and a slight decrease in the size of
markedly nonhomogeneous liver metastases was evident after
therapy (Panel A: T2-weighted image; Panel B: T1-weighted,
image).
FIGURE 10. Magnetic resonance imaging in Patient 6. Over a period of 2–6 months, despite some initial increase in size, the lesions demonstrated a higher
signal on T2-weighted images (A) and a decrease in contrast enhancement on T1-weighted images (B).
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proven to be more difﬁcult to detect than expected.
Second, the fact that the response may be slow, and
also may be preceded by some initial increase in the
size of the lesions or may not result in a substantial
decrease in tumor volume, could result in clinical
complications. For example, a spinal chordoma may
compress the spinal cord by enlarging in the early
phases of therapy. More important, as observed in the
ﬁrst two cases reported in the current series, even
major tumor liquefaction, if occurring within large
lesions, may give rise to adverse clinical consequences
and ultimately be detrimental. Indeed, this ﬁnding
occasionally also is observed in patients with GIST
who have enormous tumors. The persistence of these
masses, although not vital, occasionally may be of
little help to the patient, and local complications may
be of major signiﬁcance. Thus, the clinical utilization
of molecularly-targeted therapy always should con-
sider both its peculiar pattern of response and the
clinical presentation in the speciﬁc patient.
On the basis of these preliminary results, a formal
Phase II assessment of imatinib mesylate in patients
with chordoma is currently underway. This will allow
for the veriﬁcation of how frequently, to which degree,
and in which way molecularly-targeted therapy is ac-
tive in this disease entity. Indeed, in light of the lack of
conventional medical therapies for such a rare dis-
ease, there is a clinical need to be urgently met and,
most likely, even what has been reported in the cur-
rent small series of cases will prompt individualized
clinical decisions in selected patients with advanced
chordoma. However, it would be of vital importance
to prospectively register all those patients who would
be treated with imatinib mesylate. Furthermore, pat-
terns of tumor response as discussed herein need to
be considered, so that tumor responses are not
missed. Most important, clinicians must be aware of
the fact that even major tumor liquefaction within a
large tumor mass might not necessarily translate into
substantial medium-term beneﬁts for patients with
very advanced disease. It is likely that this therapy
should be utilized at an earlier stage of disease. In
future clinical investigations, it might be wise, espe-
cially in the case of so rare a neoplasm, to evaluate the
antitumor activity of imatinib mesylate within multi-
disciplinary approaches, including surgery and/or ra-
diation therapy.
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